YENOM NOTICIAS

Qué está moviendo el mercado.

Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.

NMRD
Limpiar

Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.

globenewswire.comPOSITIVO

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the…

globenewswire.comPOSITIVO

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and…

globenewswire.comPOSITIVO

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor…

globenewswire.comPOSITIVO

Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporti…

globenewswire.comPOSITIVO

Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lif…

globenewswire.comPOSITIVO

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporti…

globenewswire.comPOSITIVO

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporti…

globenewswire.comPOSITIVO

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporti…

globenewswire.comPOSITIVO

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting persona…

globenewswire.comPOSITIVO

Nemaura Medical Announces SFDA Approval of sugarBEAT®

Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor…

globenewswire.comPOSITIVO

Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update

Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor…

globenewswire.comPOSITIVO

Nemaura Medical Secures $6.5m in Non-Dilutive Funding

Loughborough, England, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching…

finance.yahoo.comPOSITIVO

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

Nemaura Medical, Inc Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wea…

globenewswire.comPOSITIVO

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor…

finance.yahoo.comPOSITIVO

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

Nemaura Medical, Inc LOUGHBOROUGH, June 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction…

globenewswire.comPOSITIVO

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

LOUGHBOROUGH, June 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces…

globenewswire.comPOSITIVO

Nemaura Medical to Participate at the Collision Conference in Toronto June 26-29, 2023

LOUGHBOROUGH, June 22, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces that it will be p…

finance.yahoo.comPOSITIVO

Nemaura Medical to Participate at the Collision Conference in Toronto June 26-29, 2023

Nemaura Medical, Inc LOUGHBOROUGH, June 22, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announ…

finance.yahoo.comPOSITIVO

Nemaura Medical to Exhibit and Provide Live Product Demonstrations of Its Non-invasive Glucose Sensor at the 83rd Scientific Sessions of the American Diabetes Association June 23-26, 2023

Nemaura Medical, Inc LOUGHBOROUGH, June 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors an…

globenewswire.comPOSITIVO

Nemaura Medical to Exhibit and Provide Live Product Demonstrations of Its Non-invasive Glucose Sensor at the 83rd Scientific Sessions of the American Diabetes Association June 23-26, 2023

LOUGHBOROUGH, June 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personal…

finance.yahoo.comPOSITIVO

Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton

Nemaura Medical, Inc LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors a…

globenewswire.comPOSITIVO

Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton

LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting persona…

finance.yahoo.comPOSITIVO

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement

Nemaura Medical, Inc LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors a…

globenewswire.comPOSITIVO

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement

LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting persona…

finance.yahoo.comPOSITIVO

Nemaura Medical Announces Receipt of Notice from Nasdaq

Nemaura Medical, Inc LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors an…

globenewswire.comPOSITIVO

Nemaura Medical Announces Receipt of Notice from Nasdaq

LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personal…

finance.yahoo.comPOSITIVO

Nemaura Medical, Inc. (NMRD) Reports Q3 Loss, Lags Revenue Estimates

Nemaura Medical, Inc. (NMRD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.…

finance.yahoo.comPOSITIVO

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

Nemaura Medical, Inc Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable s…

globenewswire.comPOSITIVO

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting…

finance.yahoo.comPOSITIVO

Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference

Nemaura Medical, Inc Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting persona…

globenewswire.comPOSITIVO

Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference

Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and w…

finance.yahoo.comPOSITIVO

Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

Nemaura Medical, Inc LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors an…

globenewswire.comPOSITIVO

Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personal…

finance.yahoo.comPOSITIVO

Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

Nemaura Medical, Inc LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors an…

globenewswire.comPOSITIVO

Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personal…

finance.yahoo.comPOSITIVO

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet

Nemaura to integrate its proBEATTM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. LOUGHBOROUGH, England, January 26, 2023--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)("Nemaura" or the "C…